• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Metronidazole has no antibacterial effect in Cornell model murine tuberculosis.

作者信息

Dhillon J, Allen B W, Hu Y M, Coates A R, Mitchison D A

机构信息

Department of Medical Microbiology, St George's Hospital Medical School, London, UK.

出版信息

Int J Tuberc Lung Dis. 1998 Sep;2(9):736-42.

PMID:9755928
Abstract

SETTING

Experiments in vitro on the bactericidal activity of metronidazole and in the Cornell model of murine tuberculosis.

OBJECTIVE

To assess the sterilising activity of maximal metronidazole dosage and its activity against bacilli held dormant by immunity in the mouse.

DESIGN

In vitro experiments showed that metronidazole was only bactericidal at attainable concentrations (50-100 microg/ml) under anaerobic conditions. In the Cornell model, isoniazid 25 mg/kg and high dosage pyrazinamide 1000 mg/kg was given in the diet with and without 1500 mg/kg metronidazole for the initial 14 weeks of sterilising chemotherapy. In the subsequent sterile state, metronidazole at 0, 100 and 250 mg/kg was given by daily gavage for 6 weeks. Finally, the mice were given 3 weeks of high dosage steroids and their organs were cultured in selective liquid medium.

RESULTS

Metronidazole had no activity either in the initial sterilising phase or in the subsequent sterile state.

CONCLUSION

The O2 tension in the cellular lesions of murine tuberculosis is unlikely to be sufficiently low to allow metronidazole to act. Its activity should be assessed in caseous lesions.

摘要

相似文献

1
Metronidazole has no antibacterial effect in Cornell model murine tuberculosis.
Int J Tuberc Lung Dis. 1998 Sep;2(9):736-42.
2
Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.吡嗪酰胺在潜伏性和耐利福平结核分枝杆菌模型中的杀菌作用
Int J Tuberc Lung Dis. 2006 Mar;10(3):317-22.
3
The curious characteristics of pyrazinamide: a review.吡嗪酰胺的奇特特性:综述
Int J Tuberc Lung Dis. 2003 Jan;7(1):6-21.
4
[Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].[结核分枝杆菌在感染结核分枝杆菌的H37RV小鼠中使用三种一线药物(利福平、异烟肼、吡嗪酰胺)治疗后持续存在的实验证据]
Probl Tuberk Bolezn Legk. 2004(3):32-7.
5
Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.铁负荷对异烟肼或乙胺丁醇治疗小鼠结核病活性的影响。
Int J Tuberc Lung Dis. 2003 Jun;7(6):575-9.
6
Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.阿司匹林和布洛芬可增强吡嗪酰胺对小鼠结核病的治疗效果。
J Antimicrob Chemother. 2007 Feb;59(2):313-6. doi: 10.1093/jac/dkl486. Epub 2006 Dec 21.
7
Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.甲硝唑对结核分枝杆菌的休眠细胞具有杀菌作用。
Antimicrob Agents Chemother. 1994 Sep;38(9):2054-8. doi: 10.1128/AAC.38.9.2054.
8
Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis.异烟肼调控基因在药物处理的休眠结核分枝杆菌中的表达改变
J Antimicrob Chemother. 2008 Feb;61(2):323-31. doi: 10.1093/jac/dkm485. Epub 2007 Dec 21.
9
Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice.双氯芬酸单独及与链霉素联合使用对小鼠体内结核分枝杆菌的活性。
Int J Antimicrob Agents. 2007 Oct;30(4):336-40. doi: 10.1016/j.ijantimicag.2007.04.016. Epub 2007 Jul 17.
10
Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG.
J Antimicrob Chemother. 2000 Dec;46(6):917-9. doi: 10.1093/jac/46.6.917.

引用本文的文献

1
One Size Fits All? Not in Modeling of Tuberculosis Chemotherapeutics.一概而论?在结核病化学疗法建模中并非如此。
Front Cell Infect Microbiol. 2021 Mar 16;11:613149. doi: 10.3389/fcimb.2021.613149. eCollection 2021.
2
Preclinical Efficacy Testing of New Drug Candidates.新药候选物的临床前疗效测试。
Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0034-2017.
3
Targeting Phenotypically Tolerant Mycobacterium tuberculosis.针对表型耐受的结核分枝杆菌。
Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TBTB2-0031-2016.
4
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.结核病病理学、微环境及治疗反应的异质性
Immunol Rev. 2015 Mar;264(1):288-307. doi: 10.1111/imr.12252.
5
Assessment of the Efficacy of New Anti-Tuberculosis Drugs.新型抗结核药物疗效评估
Open Infect Dis J. 2008 Dec;2:59-76. doi: 10.2174/1874279300802010059.
6
Metronidazole validates drugs targeting hypoxic bacteria for improved treatment of tuberculosis.甲硝唑验证了针对缺氧细菌的药物,以改善结核病的治疗。
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):13890-1. doi: 10.1073/pnas.1211081109. Epub 2012 Aug 15.
7
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.SQ109 的发现和开发:一种具有全新作用机制的新型抗结核药物。
Future Microbiol. 2012 Jul;7(7):823-37. doi: 10.2217/fmb.12.56.
8
Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.利用 C3HeB/FeJ 小鼠评估坏死性肉芽肿形成的小鼠模型,用于测试抗结核分枝杆菌药物。
Antimicrob Agents Chemother. 2012 Jun;56(6):3181-95. doi: 10.1128/AAC.00217-12. Epub 2012 Apr 2.
9
Models of latent tuberculosis: their salient features, limitations, and development.潜伏性结核病模型:其显著特征、局限性及发展
J Lab Physicians. 2011 Jul;3(2):75-9. doi: 10.4103/0974-2727.86837.
10
Nitroimidazoles for the treatment of TB: past, present and future.硝基咪唑类药物治疗结核病:过去、现在和未来。
Future Med Chem. 2011 Sep;3(11):1427-54. doi: 10.4155/fmc.11.90.